Developing a Vaccine to Prevent Covid-19 Disease

Vaccination against COVID-19 aims to produce an initial immune response to enable the body to quickly respond to attack and destroy SARS-CoV-2 whenever the vaccinated individual is later infected with the virus. All vaccines aim to expose the body to an agent, called an antigen, to provoke an initial immune response. In the initial immune response, the vaccinated individual produces antibodies and effector lymphocyte cells. Both the antibodies and the effector lymphocyte cells attack and destroy the antigen – in this case, the SARS-CoV-2 virus. Two major types of lymphocytes involved in vaccination response are the B cells, which produce antibodies, and the T cells, which directly attack the antigen. After the initial immune response following vaccination, the effector lymphocytes become memory cells, which remain in the body and retain the ability to attack the antigen upon a subsequent infection.

Vaccines against COVID-19 are designed based on an understanding of the SARS-CoV-2 viral structure. Like all viruses, the SARS-CoV-2 virus is a simple structure. It consists a core encased by a protein envelope. The core consists of the genetic code material ribonucleic acid (“RNA”) combined with nucleocapsid protein. The envelope is comprised of membrane protein, envelope protein, and spike (“S”) protein. The S proteins indeed resemble spikes and stud the virus envelope, giving the virus its crown- or corona-like appearance. The spikes are essential to the process whereby the coronavirus invades its host. Once the virus enters the human body, the spikes attach to cellular receptors, allowing the virus to enter the cell, begin to replicate, and cause the symptoms of COVID-19 disease in the human host.

Vaccines against SARS-CoV-2 infection use several platforms. The SARS-CoV-2 vaccine platforms under development include the following: inactivated virus; protein-based; viral vector; and nucleic acid-based. An inactivated virus is treated with chemical compounds that render it inactive but still able to stimulate the body’s immune system to respond. Protein-based vaccines involve injecting fragments of the SARS-CoV-2 protein envelope into the body. Viral vector and nucleic acid-based viruses are developed by genetic engineering.

Genetic engineering techniques facilitated rapid development of SARS-CoV-2 vaccines. Genetically-engineered viruses are based on either viral RNA or deoxyribonucleic acid (DNA). Molecular biologists use the viral RNA code as a template to create the DNA for DNA-based vaccines. In designing genetically-engineered vaccines against COVID-19, scientists create DNA or RNA polymers that code for the SARS-CoV-1 S protein. RNA vaccines are encased in a lipid capsule. DNA vaccines can be given as part of an adenovirus “vector.” An adenovirus is a type of virus that causes mild respiratory infections. Using genetic engineering techniques, DNA is incorporated into the adenovirus. Both encapsulated RNA vaccines and adenovirus vector vaccine particles are given by IM injection. The DNA or RNA from these genetically engineered vaccines is able to enter the subject’s cells. Within the subject’s cells, the DNA or RNA codes for the viral S protein, which is released into the systemic circulation. The body then initiates an immune response to the viral protein which it synthesized internally.

Clinical trials of vaccines against COVID-19 are designed to establish vaccine safety and effectiveness. In the US, drug development proceeds through a preclinical and clinical phase. Preclinical studies are conducted (1) with laboratory reagents or tissue cell cultures (“in vitro” or “test tube”); and (2) in experimental animals, usually mice, rats, and nonhuman primates. Clinical trials are designated as “early” or “late” stage. Early stage Phase I trials use single-doses in healthy normal subjects; involve single doses of the vaccine; and focus on safety. Early stage Phase II trials establish effectiveness in addition to safety and can use single or multiple doses. The late stage Phase III trials are large adequate and well-controlled trials required by law to establish safety and effectiveness for vaccine licensing. Current thinking is that it is not ethical to challenge subjects with exposure to COVID-19 after vaccination. Finally, for vaccine development, both Phase II and Phase III trials include placebo controls. Informed consent is crucial to these trials. Subjects should be fully informed of the benefits and risks of the trial and should be able to decide not to participate in the trial or withdraw at any time.

Several published reports of completed Phase II clinical trials of COVID-19 vaccines showed good safety and effectiveness. ModernaTX (“Moderna”), CanSino, and Oxford University (“Oxford”) published in peer-reviewed clinical journals results of Phase II trials of COVID-19 vaccines. All three vaccines were genetically engineered and coded for the SARS-CoV-2 S protein. Moderna used an RNA vaccine. CanSino used a nonreplicating Ad5 adenovirus vector DNA vaccine. A5 is a type of adenovirus that causes mild respiratory infections in humans. Oxford’s vaccine is a nonreplicating adenovirus vector, consisting of DNA delivered by the ChAdOx1 adenovirus, which infects chimpanzees. The trials enrolled from 45 to over 1000 healthy male and female subjects from 18 to 60 years of age and included both treatment groups and placebo groups. Moderna and Oxford gave two doses; an initial dose and a booster 28 days later. CanSino gave single doses. Follow-up was to 56 days. The most common local adverse events were pain and tenderness at the injection site. The most common systemic adverse events were headache, muscle ache, chills, fatigue, joint pain, and fever. The majority of adverse events were mild-to-moderate and resolved within several days.  Oxford found that giving acetaminophen for the first 24 hours after dosing reduced many of the adverse events. All three vaccines produced strong T cell responses and high antibody titers against the S protein and against live SARS-CoV-2 virus. Vaccines produced higher antibody responses than convalescent plasma samples from recovered COVID-19 patients. However, antibody titers against SARS-CoV-2 virus in senior subjects were about half those observed in younger subjects.

The World Health Organization (“WHO”) maintains a website that tracks worldwide trials of vaccine candidates against COVID-19 and lists 6 Phase III trials in progress. The vaccine candidates in Phase III are from Moderna, AstraZeneca/Oxford, Pfizer/BioNTech (“Pfizer”), Sinovac, and Sinopharm. The Pfizer vaccine is an RNA-based vaccine. The Sinovac and Sinopharm vaccines are chemically-inactivated viruses. Many scientists believe that inactivated virus vaccines induce a stronger immune response than genetically engineered vaccines. The Moderna and Pfizer Phase III trials are taking place in US. AstraZeneca/Oxford will conduct one Phase III trial in the UK and one in Brazil. The Sinovac trial will also take place in Brazil. The Sinopharm trial will take place in the United Arab Emirates. The Phase III trials will be run at multiple clinical sites and will enroll from 2,000 to 30,000 healthy male and female subjects, of ages ranging from 18 years to “over 70.” Subjects will receive initial and booster vaccinations. The Moderna trial will enroll health care workers at high risk of contracting COVID-19. All other trials will use subjects in the community. All trials will investigate safety, anti-SARS-CoV-2 antibody titers in serum, and T-cell responses in blood. Subjects will be monitored for 1-2 years after immunization. A primary endpoint in the trials will be the percentage of subjects who contract COVID-19 in the community.

As per the WHO website, 10 different Phase II trials and 10 different Phase I trials of COVID-19 vaccine candidates are in progress. Companies running Phase II trials are Anhui of China; the Institute of Medical Biology of China; Inovio of South Korea; Takara Bio of Japan; Cadila of India; Genexine of South Korea; Novavax of Australia; Kentucky Bioprocessing of the US; Arcturas of Singapore; and Janssen/Johnson & Johnson of the US. Platforms include protein subunit, inactivated virus, DNA-based, RNA-based, and adenovirus vector. Primary endpoints are safety; secondary endpoints are antibody titers and T-cell responses. Companies running Phase I trials are based in Russia, Australia, the UK, Belgium, China, Canada, and Taiwan. Platforms include adenovirus vector, protein subunit, and RNA. A novel platform being tested in Phase I by Medicago of Canada is plant-derived virus-like particles, which are thought to produce a strong immune response despite being plant-derived. The WHO website also states that, as of July 31, 2020, 139 vaccine candidates are in in preclinical development worldwide.

The FDA is facilitating rapid availability of COVID-19 vaccines for the US. The Agency posted a Guidance for Industry on how to develop vaccines for licensing. The FDA has stated that it may consider granting an Emergency Use Authorization (“EUA”) for vaccines. Under an EUA, a vaccine would be made available to the public even though it has not yet undergone all the clinical testing normally required for licensing. The FDA has also stated that it will consider granting licenses for COVID-19 under the Accelerated Approval program before all the Phase III testing is complete. For both an EUA and Accelerated Approval, the vaccine must show preliminary evidence of safety and effectiveness in humans and strict criteria must be met.

Ethical issues arise once a vaccine is available. For example, if initial quantities are limited, this raises questions of prioritization for distribution. Priority might be granted to health care workers and other essential workers. Priority also might be granted to the more vulnerable populations, such as the elderly and those with pre-existing conditions. An additional question is how low-cost vaccines can be made available to all.

In summary, a tremendous worldwide effort is underway to rapidly develop a safe and effective vaccine against COVID-19 disease. Vaccines are based on a variety of different platforms. The most rapid progress has been made with genetically engineered vaccines. Several developers showed good vaccine safety and effectiveness in early-stage clinical trials and are now conducting late-stage clinical trials. Many other vaccine candidates are being actively studied in early-stage clinical trials. In vitro and animal studies are underway for even more vaccine candidates. Government and industry are collaborating to expedite vaccine availability, and it is conceivable that a vaccine against COVID-19 could be available by late 2020-early 2021. It is hoped that government and industry will also collaborate effectively to make affordable vaccines available to as many individuals as possible.

Corticosteroid Hormones and COVID-19

CORTICOSTEROID HORMONES AND COVID-19

Introduction. The corticosteroid hormone drugs Dexamethasone and Methylprednisolone have both been successfully used to treat COVID-19 patients. Dexamethasone, approved by the FDA in 1958, is marketed for treating severe or incapacitating allergic conditions. Methylprednisolone, approved by the FDA in 1959, is marketed for treating severe allergic conditions and some types of autoimmune diseases. Corticosteroid drugs are thought to effectively treat these diseases because of their ability to modify the body’s immune response.  Since a strong sustained immune response causes many of the life-threatening symptoms of COVID-19, clinicians began to add low-dose corticosteroids to treatment regimens. Thus, the objective of low-dose corticosteroid treatment in COVID-19 patients to control disease progression by modifying the immune response. A strong sustained immune response can occur in COVID-19 disease as the body’s immune system attempts to destroy the SARS-CoV-2 virus infection. Unfortunately, a sustained immune response can begin to damage body tissues, in particular the lungs. As lungs become more severely damaged, this leads to pneumonia, which can become life-threatening. Adding immune response modulators such as corticosteroids to a COVID-19 treatment regimen should improve clinical condition and survival by reducing the immune response that is responsible for the damaging symptoms of the disease.

Only low doses of corticosteroids are recommended for treating COVID-19 disease because the drugs can cause serious toxicities. Dexamethasone and Methylprednisolone are synthetic versions of corticosteroid hormones that the body produces naturally. Among other effects, corticosteroids regulate glucose metabolism in the body as well as the immune response. Thus, the toxic effects of corticosteroid drugs are extensions of their beneficial properties – notably, hyperglycemia and immune response suppression. Both of these responses are harmful. Sustained hyperglycemia, which means that too much glucose is circulating in the blood, can damage the heart, eyes, nerves, and kidneys and even lead to diabetic coma. Suppression of the immune response can lead to severe infections, as the body’s infection-fighting ability is impaired. Thus, it is crucial in corticosteroid therapy of COVID-19 disease to use only low doses of the drugs.

Effects of Methylprednisolone on COVID-19 disease progression were studied in a small trial conducted in China. This was a retrospective observational trial in COVID-19 patients with pneumonia and severe disease, of whom 26 received Methylprednisolone and 20 did not. The doses of Methylprednisolone were low, ranging from 1-2 mg/kg given intravenously over 5-7 days. Although mortality was low and similar in the two groups (about 6%), clinical improvement was more rapid in the Methylprednisolone-treated patients. CT scans of lungs showed that the ground-glass opacities that occur in COVID-19 patients disappeared more rapidly in the Methylprednisolone-treated patients. A lower percentage of Methylprednisolone-treated patients needed mechanical ventilation than control patients (12% versus 35%). In addition, Methylprednisolone-treated patients spent less time on the ventilators, less time in the ICU, and were discharged more rapidly from the hospital than the control patients (median stay of 14 days versus median stay of 22 days). Finally, levels of chemical substances that circulate in the blood in high amounts during a sustained immune response, notably interleukin-6, C-reactive protein, and ferritin, dropped twice as rapidly in Methylprednisolone-treated patients as in control. The investigators added immunoglobulin and thymosin (only approved in China) to the Methylprednisolone regimens to prevent suppression of the immune response. Both immunoglobulin and thymosin are used in clinical practice in China to increase the immune response. No Methylprednisolone-related adverse events occurred in this trial.

Effects of Dexamethasone on mortality in COVID-19 were studied in a large clinical trial in the United Kingdom. Dexamethasone reduced mortality in severely-infected COVID-19 patients who were treated in the United Kingdom (“UK”) Randomised Evaluation of COVID-19 Therapy (“RECOVERY”) trial. The RECOVERY trial is investigating possible treatments for COVID-19 in patients hospitalized in at least 175 clinical centers throughout the UK. Up to 12,000 patients will be enrolled in the trial, which is open to adult, elderly, and pediatric patients (older than one year of age). Recruitment for the study began on March 19, 2020. The treatments being studied are Lopinavir/Ritonavir, Hydroxychloroquine, Azithromycin, Tocilizumab, Convalescent Plasma, and Dexamethasone. The trial includes a control group of 4321 COVID-19 patients who are receiving only standard hospital care for their symptoms. In the Dexamethasone group, 2140 patients received oral Dexamethasone at 6 mg/day for 10 days.

Dexamethasone treatment in the RECOVERY trial was stopped early because Dexamethasone significantly improved survival in COVID-19 patients. The RECOVERY trial Steering Committee concluded that enough patients were enrolled to show that Dexamethasone improved patient survival, assessed at Day 28 of the study observation period. Thus, as of June 16, 2020, the investigators stopped recruiting patients for the Dexamethasone treatment group. The investigators found that Dexamethasone, compared to control, reduced mortality by 35% in patients on mechanical ventilators and by 20% in patients receiving oxygen only. This means that, for every 8 COVID-19 patients requiring treatment with ventilators, Dexamethasone treatment will prevent one death, and; for every 24 COVID-19 patients that need supplementation with oxygen only, Dexamethasone treatment will prevent one death. The UK Government’s Chief Scientific Advisor concluded that Dexamethasone is the first drug shown to reduce mortality from COVID-19. The RECOVERY trial principal investigators recommend that Dexamethasone should become the standard of care for COVID-19 patients who are sick enough to require oxygen treatment. In the interest of advancing the public health, the investigators plan to soon publish the full Dexamethasone treatment results from the RECOVERY trial.

Summary and Conclusion. Limited clinical trial results show that both Methylprednisolone and Dexamethasone are effective for treating severe COVID-19 disease. Methylprednisolone-treated patients recovered faster than controls. Dexamethasone improved patient survival compared to controls. Methylprednisolone treatment is given IV; Dexamethasone is easier to administer as it can be given orally. As both suppress the immune system, patients should be monitored for infections while undergoing treatment. Also, since both affect the immune response to COVID-19, it is important to administer either at an optimal time period during disease progression in order to achieve maximal benefit. Larger well-controlled trials are needed to further explore the role of corticosteroid hormones in COVID-19 disease treatment, either as monotherapy or as part of a combination regimen.

 

Safe Zooming in Quarantine Times

By CHHS Extern Nicky Arenberg Nissin

With billions of people around the globe staying home due to the Covid-19 pandemic, an increasing amount of social and business meetings have moved to the different video conferencing platforms available today. Among this wide software offer, Zoom has become one of the most popular options: as the go-to app for many schools and colleges, employers, and even some governments, this app has also become one of the most commonly used for social and cultural gatherings. With Zoom’s ubiquity on these pandemic-times, several privacy and security issues have been identified.

For instance, Zoom’s privacy policy has recently been the target of concerns by Consumer Reports (CR) and the Electronic Frontier Foundation (EFF). The main complaint was that app’s terms included the right to collect the video and text content of Zoom meetings, and to share it or use it for advertisement or other business purposes. In the same vein, a Vice investigation exposed that Zoom’s iOS app was sending some user data and analytics to Facebook, regardless of whether they had a linked Facebook account or not. Zoom’s reaction was to quickly make some changes; the company updated their iOS app to stop this sharing with Facebook, and–maybe more importantly–they made some “clarifying updates” to their privacy policy, ostensibly addressing these issues.

Another thing to consider is the power other users and meeting host have to record video, audio, screenshots and chat messages during sessions. By having an open mic or camera, Zoom users are exposed to having their privacy breached during meetings, the contents of private communications compromised, and–as we have seen lately–to potentially become viral sensations. To address this privacy issue, the best practice is for users to activate their mic only when speaking, and–if one decides to activate the camera as well–to use the app’s built-in feature that lets them choose a photo as their video background. This way–by controlling the audio and video being broadcasted to the rest of the meeting–users can minimize the risk of having unintended disclosures or leaks of private information.

The new reality of work and social Zooming has also come with cybersecurity problems. On one hand, there has been a surge in Zoom site spoofing and phishing attacks by cybercriminals, specifically targeting people working from home. These are pretty run-of-the-mill attacks–like the common Netflix or App Store spoof phishing emails–and they can be avoided in the same ways.

On the other hand, internet trolls have started to crash into Zoom meetings by exploiting the app’s settings. In fact, this problem has become so prevalent that Zoom specially created a guide for users to avoid getting uninvited guests. It is evident that the unwanted display of pornography, threatening language or hate speech during a meeting can be disrupting; moreover, the fact that these trolls can also record and publish user reactions to them is concerning, especially on the many K-12 schools using the app.

As the Covid-19 pandemic continues to expand, our dependence on the tools that–like Zoom–allow us to study, work, and socialize from home will deepen. In turn, users will be increasingly vulnerable to these and other privacy and security issues. As we have seen in the past few days, law enforcement is already aware of this situation, and have started investigating the associated criminal activity. In the meantime, users must learn how to use this technology safely and responsibly, keeping up with the associated risks and their management.

Defense Production Act: A Solution to the COVID-19 Personal Protective Equipment Shortage?

On Friday, March 20 President Donald Trump invoked the Defense Production Act to help increase production of much needed equipment to address the COVID-19 pandemic. The Defense Production Act of 1950 (“DPA”) was enacted to prepare and respond to “both domestic emergencies and international threats to national defense”1 by developing the capacity to procure essential equipment to addressing an emergency.  Through the DPA, the President is authorized to prioritize certain existing contracts held by the government as well as allocate resources in a manner in which he deems “necessary or appropriate to promote the national defense.”2 In addition to prioritizing fulfillment of existing government contracts, the President is authorized to control general distribution of scarce materials in the civilian market if those materials are critical to the national defense. In addressing the COVID-19 pandemic, which continues to expand as hospitals face critical shortages of test kits and personal protective equipment (PPE), the DPA offers an additional tool for the federal government in increasing capacity.  

The DPA provides the Trump Administration the following discrete powers to rapidly increase production of the test kits and personal protective equipment necessary to curb the COVID-19 pandemic:  

  • Prohibition on Hoarding Scare Materials 

Last week, as many jurisdictions enacted policies implementing strict social distancing, many Americans stockpiled essential goods in preparation for the COVID-19 pandemic. In addition to essentials like toilet paper, some Americans have also purchased PPE that our healthcare system vitally needs. Sellers like Amazon have been selling out of N95 respirators, resulting in shortages at hospitals across the country and leading to healthcare workers operating in unsafe conditions on the frontline of the pandemic.  Under the DPA, the President is authorized to ration some of these vital supplies, making it unlawful to stockpile designated goods beyond what is deemed reasonable for home consumption or business use. In other words, the President has the power to limit the amount of hand sanitizer, sterile gloves, or respirators purchased for personal benefit rather than the collective safety of our healthcare workers and first responders.  

  • Prioritization of Contracts 

One of the main powers of the DPA authorizes the President to prioritize the fulfillment of government contracts by a vendor. For example, the federal government has existing contracts with large suppliers that provide goods ranging from personal protective equipment to administrative supplies. Under the DPA, the President can instruct the supplier to focus all production on the necessary PPE for addressing the pandemic.  

  • Loans to Enhance Production 

In addition to prioritizing contracts, the DPA authorizes the President to guarantee loans to businesses in order to increase their production capabilities. This could include loans that hire more workers, purchase materials, or equipment to expedite or expand the production of necessary goods like N95 respirators, ventilators, and ventilator valves.  

Additionally, the President is authorized to impose price controls on the scare goods necessary for addressing this pandemic with Congressional approval. Penalties for failing to comply with actions set out by the DPA could result in a $10,000 fine or up to one-year imprisonment.  

The DPA is a vital tool to accelerate production of materials necessary for addressing the COVID-19 pandemic. As Dr. Bill Frist outlined Friday, the federal response over the weekend will be critical in addressing the PPE shortages our healthcare personnel face during the COVID-19 pandemic. However, there are inevitably lags between the measures to enhance production and providing the supplies to our hospitals and healthcare facilities in need. To ensure that our healthcare providers are appropriately protected, the rest of the population should follow the CDC guidance for their community and refrain from purchasing unnecessary PPE and consider donating PPE that they do not need to a local hospital that does. 

President Trump at the White House

The Meaning of Last Week’s COVID-19 Emergency Declaration

By CHHS Extern Sharon Sidhu

President Trump declared a national emergency over the coronavirus COVID-19 pandemic on Friday afternoon, “unleash[ing] the full power of the federal government.”

This action, under the authority of the Stafford Act, opened up access to up to $50 billion for states, territories, and localities, to use towards the shared fight against the spread of COVID-19. The Stafford Act frees up federal funds when federal assistance is needed to supplement State and local efforts in providing emergency services for the protection of lives, public health and safety, or to contain the threat of a catastrophe in the United States.

The White House wrote a letter to the director of the FEMA, and the secretaries of the Department of Homeland Security, Department of Treasury and the Department of Health and Human Services outlining four major takeaways from the emergency declaration.

First, the letter states FEMA may take emergency protective measures and provide assistance under the authority of Sections 502 and 503 of the Stafford Act. Under Section 502, the President can direct any Federal agency to use its resources (including personnel, equipment, supplies, and facilities) “in support of State and local emergency assistance efforts to save lives, protect property and public health and safety, and lessen or avert the threat of a catastrophe, including precautionary evacuations.” This includes providing technical and advisory assistance to State and local governments for the performance of essential community services, issuance of warnings of risks or hazards, dissemination of public health and safety information, and management of immediate threats to public health and safety. Section 502 also prompts the federal government to assist State and local governments in the distribution of medicine, food and other consumable supplies, and emergency assistance. Section 503 limits the amount of federal assistance not to exceed $5 million for a single emergency, unless the President deems it necessary, which in the case of COVID-19, President Trump has.

Second, the letter encourages all State and local governments to activate their Emergency Operation Centers and to review their emergency preparedness plans. President Trump’s declaration also instructs hospitals nationwide to activate their emergency preparedness contingency plans in order to meet the needs of Americans who have and may have contracted COVID-19. President Trump also said the Health and Human Services Secretary Alex Azar will be able to “waive provisions of applicable laws and regulations to give doctors, all hospitals, and health care providers maximum flexibility to respond to the virus.” These waivers include waivers to access limits on numbers of beds and lengths of stays in hospitals, as well as waivers to rules on bringing in additional physicians at certain hospitals as needed.

Third, the letter instructs the Department of Treasury to provide relief from tax deadlines to Americans who have been adversely affected by the COVID-19 emergency, pursuant to 26 U.S.C. 7508(A)(a), which grants the Department of Treasury to postpone certain deadlines for those who have been affected by a federally declared disaster.

Finally, in his letter, President Trump encouraged all governors and tribal leaders to consider requesting Federal assistance under section 401(a) of the Stafford Act. Section 401(a). Section 401(a) requires requests for a declaration by the President that a major disaster exists to be made by the Governor of the affected State. The request needs to be based on the conclusion that the disaster “is of such severity and magnitude that effective response is beyond the capabilities of the State” such that Federal assistance is necessary. The President may grant the request of the Governor and declare that a major disaster or emergency exists, and thereafter direct federal funds to provide relief assistance, as well as assistance in the distribution of medicine, food, and emergency assistance to the states.